Floatz logo

HYDROMORPHON

Malignant Solid Neoplasm

M.D. Anderson Cancer CenterSmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
81/ 100

Competitive context

1411 Active assets in the Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Nabiximols
Jazz Pharmaceuticals
Phase 3BBB
Inno-206
M.D. Anderson Cancer Center
Phase 2BB
Vitamin B6
M.D. Anderson Cancer Center
Phase 4BB
PROPOFOL
Hong Kong Children's Hospital
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB

View all 50 →

Same molecule, other indications

HYDROMORPHON is also rated in:

substance-related disorderDormant
BBB
Indicative ·
74 / 100
View asset →
Low Back PainDormant
BBB
Indicative ·
72 / 100
View asset →
Analgesics, OpioidDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →